Hierarchical classification and coding of clinical activities of acute care for stroke

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **First level** | **Second level** | **Third level** | **Forth level** | **Fifth level** |
| C.T. Operation | C.T.1. Nursing | C.T.1.1. Grading nursing | C.T.1.1.1. Grade Ⅰ nursing |  |
| C.T. Operation | C.T.1. Nursing | C.T.1.1. Grading nursing | C.T.1.1.2. Grade Ⅱ nursing |  |
| C.T. Operation | C.T.1. Nursing | C.T.1.1. Grading nursing | C.T.1.1.3. Grade Ⅲ nursing |  |
| C.T. Operation | C.T.1. Nursing | C.T.1.1. Grading nursing | C.T.1.1.4. Special nursing |  |
| C.T. Operation | C.T.1. Nursing | C.T.1.2. Special nursing | C.T.1.2.1. Oral nursing |  |
| C.T. Operation | C.T.1. Nursing | C.T.1.2. Special nursing | C.T.1.2.2. Sputum aspiration nursing |  |
| C.T. Operation | C.T.2. General operation | C.T.2.1. Blood collection |  |  |
| C.T. Operation | C.T.2. General operation | C.T.2.2. Oxygen inhalation |  |  |
| C.T. Operation | C.T.2. General operation | C.T.2.3. Lower gastric tube |  |  |
| C.T. Operation | C.T.2. General operation | C.T.2.4. Perineal irrigation |  |  |
| C.T. Operation | C.T.2. General operation | C.T.2.5. Replace the drainage device |  |  |
| C.T. Operation | C.T.2. General operation | C.T.2.6. Turn over and buckle back |  |  |
| C.T. Operation | C.T.2. General operation | C.T.2.7. Nursing of arteriovenous catheterization |  |  |
| C.T. Operation | C.T.3. Clinical physical therapy | C.T.3.1. Physiotherapy | C.T.3.1.1. Limb compression therapy |  |
| C.T. Operation | C.T.3. Clinical physical therapy | C.T.3.1. Physiotherapy | C.T.3.1.2. Gastrointestinal decompression |  |
| C.T. Operation | C.T.3. Clinical physical therapy | C.T.3.1. Physiotherapy | C.T.3.1.3. TDP treatment |  |
| C.T. Operation | C.T.3. Clinical physical therapy | C.T.3.2. Recovery | C.T.3.2.1. Dysarthria training |  |
| C.T. Operation | C.T.3. Clinical physical therapy | C.T.3.2. Recovery | C.T.3.2.2. Lower extremity comprehensive sports training |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.1. Clinical hematology | C.O.1.1.1. Routine blood test |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.1. Clinical hematology | C.O.1.1.2. Hematopoietic stem cell count |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.1. Clinical hematology | C.O.1.1.3. Coagulation test |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.1. Clinical hematology | C.O.1.1.4. Blood group identification |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.2. Clinical humoral test | C.O.1.2.1. Urine routine |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.2. Clinical humoral test | C.O.1.2.2. Stool routine |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.2. Clinical humoral test | C.O.1.2.3.Gastric fluid occult blood |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.1. Glycosylated hemoglobin |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.2. Determination of natriuretic peptide B |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.3. Determination of high sensitive C-reactive protein |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.4. Blood sugar |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.5. Electrolyte |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.6. Liver function |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.7. Thyroid function |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.8. Procalcitonin detection |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.9. Renal function |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.10. Myocardial enzyme spectrum |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.11. Determination of lactate in plasma |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.12. Blood gas analysis |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.13. Determination of homocysteine in blood |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.14. Blood ketone body |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.15. Serum lipids |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.3. Clinical chemistry test | C.O.1.3.16. Acetylcysteine |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.4. Clinical immunoassay | C.O.1.4.1. Infectious diseases |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.4. Clinical immunoassay | C.O.1.4.2. Anticardiolipin antibody |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.4. Clinical immunoassay | C.O.1.4.3. Sepsis combination: PCT + IL-6 |  |
| C.O. Observation | C.O.1. Lab test | C.O.1.5. Clinical microbiology | C.O.1.5.1. Sputum culture identification + drug sensitivity test |  |
| C.O. Observation | C.O.2. Pathological test | C.O.2.1. Cellular pathology | C.O.2.1.1 Fine needle aspiration cytology and diagnosis |  |
| C.O. Observation | C.O.2. Pathological test | C.O.2.2. Histopathology | C.O.2.2.1. Pathological diagnosis of biopsy |  |
| C.O. Observation | C.O.3. Image examination | C.O.3.1. X-ray examination | C.O.3.1.1. Radiography | C.O.3.1.1.1. Cervical spine CR |
| C.O. Observation | C.O.3. Image examination | C.O.3.1. X-ray examination | C.O.3.1.1. Radiography | C.O.3.1.1.2. Chest CR |
| C.O. Observation | C.O.3. Image examination | C.O.3.1. X-ray examination | C.O.3.1.1. Radiography | C.O.3.1.1.3. Lumbar CR |
| C.O. Observation | C.O.3. Image examination | C.O.3.1. X-ray examination | C.O.3.1.1. Radiography | C.O.3.1.1.4. Knee joint CR |
| C.O. Observation | C.O.3. Image examination | C.O.3.1. X-ray examination | C.O.3.1.2. X-ray fluoroscopy | C.O.3.1.2.1. Head Fluoroscopy |
| C.O. Observation | C.O.3. Image examination | C.O.3.2. CT | C.O.3.2.1. Plain scan CT | C.O.3.2.1.1. Head CT |
| C.O. Observation | C.O.3. Image examination | C.O.3.2. CT | C.O.3.2.2. Enhanced CT | C.O.3.2.2.1. Enhanced chest CT |
| C.O. Observation | C.O.3. Image examination | C.O.3.3. MRI | C.O.3.3.1. Plain scan MRI | C.O.3.3.1.1. Abdominal MRI |
| C.O. Observation | C.O.3. Image examination | C.O.3.3. MRI | C.O.3.3.2. Enhanced MRI | C.O.3.3.2.1. Enhanced Head MRI |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.1. B-ultrasound | C.O.3.4.1.1. Neck ultrasound |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.3. Gallbladder color Doppler ultrasound |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.2. Liver ultrasound |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.1. Femoral arteriovenous ultrasound |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.4. Vein ultrasound of lower extremity |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.5. Brain color ultrasound |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.6. Color Doppler ultrasound of neck |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.7. Ultrasound of external iliac artery |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.8. Ultrasound of external iliac vein |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.9. Renal color Doppler ultrasound |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.10. Pancreatic color Doppler ultrasound |
| C.O. Observation | C.O.3. Image examination | C.O.3.4. Ultrasonography | C.O.3.4.2. Color doppler ultrasound | C.O.3.4.2.11. Echocardiography |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.1. Nervous system | C.O.4.1.1. 64 lead EEG |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.1. Nervous system | C.O.4.1.2. Eye movement examination |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.1. Nervous system | C.O.4.1.3. Brainstem auditory evoked potential examination |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.1. Nervous system | C.O.4.1.4. Blink reflex |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.2. Circulatory system | C.O.4.2.1. 12 channel routine ECG |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.2. Circulatory system | C.O.4.2.2. Ambulatory blood pressure monitoring |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.2. Circulatory system | C.O.4.2.3. Blood pressure measurement |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.2. Circulatory system | C.O.4.2.4. Blood oxygen monitoring |  |
| C.O. Observation | C.O.4. Clinical examination | C.O.4.2. Circulatory system | C.O.4.2.5. ECG monitoring |  |
| C.A. Assessment | C.A.1. Neural function | C.A.1.1 NIHSS |  |  |
| C.A. Assessment | C.A.1. Neural function | C.A.1.1 FAST-ED |  |  |
| C.A. Assessment | C.A.2. Dementia | C.A.2.1 MMSE |  |  |
| C.A. Assessment | C.A.3. Depression | C.A.3.1 HAMD |  |  |
| C.A. Assessment | C.A.4. Anxiety disorder | C.A.4.1 SAS |  |  |
| C.A. Assessment | C.A.5. Patient's overall state | C.A.5.1 Critical |  |  |
| C.A. Assessment | C.A.5. Patient's overall state | C.A.5.2 Serious |  |  |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.1. Antimicrobials | C.D.1.1.1. Penicillins | C.D.1.1.1.1. Benzylpenicillin |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.1. Antimicrobials | C.D.1.1.1. Penicillins | C.D.1.1.1.2. Amoxicillin |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.1. Antimicrobials | C.D.1.1.1. Penicillins | C.D.1.1.1.3. Piperacillin |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.1. Antimicrobials | C.D.1.1.1. Penicillins | C.D.1.1.1.5. Meropenem |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.1. Antimicrobials | C.D.1.1.1. Penicillins | C.D.1.1.1.5. Piperacillin Sodium and Tazobactam Sodium |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.1. Antimicrobials | C.D.1.1.2. Cephalosporins | C.D.1.1.2.1. cefoperazone and sulbactam |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.1. Antiepileptic | C.D.1.2.1.1. Carbamazepine |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.2. Defibrase | C.D.1.2.2.1. Batroxobin |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.1. Oxiracetam |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.2. Butylphthalide |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.3. Cerebroprotein hydrolysate |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.4. Brain glycoside Carnosine |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.5. Calf serum deproteinization |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.6. Edaravone |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.7. Urinary Kallidinogenase |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.3. Neuroprotection / repair | C.D.1.2.3.8. Monosialotetrahexose ganglioside sodium |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.2. Nervous system drugs | C.D.1.2.4. Opioid receptor antagonists | C.D.1.2.4.1. Nalmefene |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.3. Cardiovascular system drugs | C.D.1.3.1. Antihypertensive | C.D.1.3.1.1. Nitrendipine |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.3. Cardiovascular system drugs | C.D.1.3.1. Antihypertensive | C.D.1.3.1.2. Irbesartan hydrochlorothiazide |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.3. Cardiovascular system drugs | C.D.1.3.1. Antihypertensive | C.D.1.3.1.3. Mannitol |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.3. Cardiovascular system drugs | C.D.1.3.2. Antiarrhythmic | C.D.1.3.2.1. Metoprolol |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.3. Cardiovascular system drugs | C.D.1.3.3. Hypolipidemic | C.D.1.3.3.1. Probucol |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.3. Cardiovascular system drugs | C.D.1.3.4. Statin | C.D.1.3.4.1. statin |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.4. Hematological system drugs | C.D.1.4.1. Thrombolysis | C.D.1.4.1.1. rt-PA |
| C.D. Drug | C.D.1. Chemicals and biological products | C.D.1.4. Hematological system drugs | C.D.1.4.1. Thrombolysis | C.D.1.4.1.2. urokinase |